Miyoshi Toru, Doi Masayuki, Hirohata Satoshi, Kamikawa Shigeshi, Usui Shinichi, Ogawa Hiroko, Sakane Kosuke, Izumi Reishi, Ninomiya Yoshifumi, Kusachi Shozo
Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
Heart Vessels. 2011 Jul;26(4):408-13. doi: 10.1007/s00380-010-0060-x. Epub 2010 Nov 10.
Adipocyte fatty acid binding protein (A-FABP) has been reported to be involved in insulin resistance, lipid metabolism, and atherosclerosis; however, little is known about the effect of medication on the change in circulating A-FABP in human subjects. We evaluated the effects of angiotensin II type 1 receptor blocker (ARB) on arterial stiffness and its association with serum A-FABP in patients with hypertension. Thirty patients newly diagnosed with essential hypertension were treated with olmesartan (20 mg/day), an ARB, for 6 months. Serum levels of A-FABP and high-sensitivity C-reactive protein (hsCRP) were examined and the cardio-ankle vascular index (CAVI), which is a marker of arterial stiffness, was also determined. Serum A-FABP at baseline was significantly correlated with the body mass index (r = 0.45, P = 0.01), homeostasis model assessment as a marker of insulin resistance (r = 0.53, P < 0.01), and systolic blood pressure (r = 0.37, P = 0.047), and tended to be correlated with low-density lipoprotein cholesterol, triglyceride, and CAVI. Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure. Multiple regression analysis revealed that the change in CAVI was independently correlated with the change in serum A-FABP. Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.
据报道，脂肪细胞脂肪酸结合蛋白（A-FABP）与胰岛素抵抗、脂质代谢和动脉粥样硬化有关；然而，关于药物对人体循环中A-FABP变化的影响却知之甚少。我们评估了1型血管紧张素II受体阻滞剂（ARB）对高血压患者动脉僵硬度的影响及其与血清A-FABP的关系。30例新诊断的原发性高血压患者接受ARB奥美沙坦（20毫克/天）治疗6个月。检测血清A-FABP和高敏C反应蛋白（hsCRP）水平，并测定作为动脉僵硬度标志物的心脏-脚踝血管指数（CAVI）。基线时血清A-FABP与体重指数显著相关（r = 0.45，P = 0.01），与作为胰岛素抵抗标志物的稳态模型评估显著相关（r = 0.53，P < 0.01），与收缩压显著相关（r = 0.37，P = 0.047），并且与低密度脂蛋白胆固醇、甘油三酯和CAVI呈正相关趋势。奥美沙坦治疗除显著降低血压外，还导致CAVI、血清A-FABP水平和hsCRP显著降低。多元回归分析显示，CAVI的变化与血清A-FABP的变化独立相关。奥美沙坦改善了高血压患者的动脉僵硬度，这可能与血清A-FABP的降低有关。
